Richmond Pharmacology is pleased to confirm our attendance at The Liver Meeting 2025,hosted by the American Association for the Study of Liver Diseases (AASLD),taking place in Washington, DC, from 7th –11th November.
Representing Richmond at The Liver Meeting:
· James Rickard,Chief Scientific Officer
James looks forward to engaging with industry and academic partners to discuss Richmond’s expertise in:
· Early-phase hepatology and metabolic liver disease trials
· First-in-human and dose-ranging studies
· Non-invasive biomarkers and digital health integration
· Regulatory strategy and multi-regional trial delivery
· Patient-focused approaches in complex liver studies
If you’re attending AASLD 2025 and seeking a clinical development partner in liver disease research, get in touch to arrange a meeting with James: info@richmondpharmacology.com
Learn more: The Liver Meeting | AASLD